Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Go back to Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals (ALNY) PT Raised to $86 at Jefferies

August 5, 2016 9:30 AM EDT

Jefferies analyst Gena Wang reiterated a Buy rating and raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ti $86.00 (from $80.00) following Q2 update which highlighted progress in clinical programs.

Wang commented, "Following recent data updates (TTR programs, CC5 and fitusiran), we continue to... More